Coronavirus / New Delta plus variant of SARS-CoV-2 identified, know the detail

New Delhi: Corona virus is constantly changing its form and now its new variants have been detected. The delta variant responsible for the second wave of corona in India has now mutated into 'Delta Plus' or AY.1, which is a new challenge for scientists. Due to the fear of this delta variant, it has come to the point of re-implementation of restrictions in many countries of the world. Not only this, in India also the second wave of corona has proved to be the most deadly.

The second wave came from 'Delta'

It is a matter of relief that there is nothing to be worried about in India as there are still very few cases of it in the country. The 'Delta Plus' variant, made from the virus mutating to Delta or 'B1.617.2', was first identified in India. This variant was responsible for the second wave of the pandemic.

While there is no indication yet of how deadly the disease can be caused by the new variant of the virus, Delta Plus is an antagonist of the 'monoclonal antibody cocktail' treatment that was recently approved in India.

spreads infection in cells

Vinod Scaria, a scientist at Delhi-based CSIR- Institute of Genomics and Integrative Biology (IGIB), tweeted on Sunday that the K417N mutation has caused the B1.617.2 variant, also known as AY.1. He said that this mutation occurred in the spike protein of SARS-CoV-2, which helps the virus to infect human cells by going inside.

Scaria wrote on Twitter, 'Variants stemming from K417N in India are not very much yet. These sequences have mostly come from Europe, Asia and America. Scaria also said that the mutation may also be related to immunity against the virus.

Shock to 'antibody cocktail' test

Immunity expert Vinita Bal said that although the test for the 'antibody cocktail' has been a setback due to the new variant of the virus, it does not mean that the virus is more contagious or it will make the disease more deadly. Vineeta Bal, a teacher at the Indian Institute of Science Education and Research, Pune, said, 'How contagious this new variant is, it will be important to test its ability to spread rapidly, or it may even reverse.'

He also said that the quality and number of antibodies that protect cells from pathogens in someone infected with the new variant are not expected to be affected by the mutation. Respiratory specialist and medical researcher Anurag Aggarwal supported Vinita Bal's point of view.

Anurag Aggarwal, director of CSIR-IGIB, said, 'There is nothing to worry about this variant of the virus in India right now.' He said that this type of virus will have to be tested from the plasma of people who have taken the full dose of the vaccine, which will know whether it is able to dodge the disease or not.